Shots:

• Sanofi Genzyme reports the new data from the company's neurology portfolio- to be presented at MSVirtual2020. The company will highlight new data on tolebrutinib (SAR442168)- supporting its potential in modulating disabling inflammatory processes within the CNS and will provide a deeper understanding of Sanofi Genzyme's current MS therapies and pipeline products
• Additionally- the company will present posters and platform presentations highlighting the studies assessing the safety- efficacy- and investigational uses of approved therapies Aubagio (teriflunomide) and Lemtrada (alemtuzumab) reinforcing the consistent- positive clinical profiles of two treatment options
• Tolebrutinib is an investigational BTK inhibitor and has demonstrated BTK binding as well as cerebrospinal fluid exposure in P-I studies. Teriflunomide is a prescription medicine used to treat RMS including clinically isolated syndrome- relapsing-remitting disease- and active secondary progressive disease in adults

­ Ref: Sanofi | Image: UPI